Valganciclovir: all 76 studies that test it
Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and IINot yet recruitingNCT07513623Phase 2
- Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV InfectionRecruitingNCT07383649Phase 2
- ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAseNot yet recruitingNCT07379203Phase 2
- Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant RecipientsRecruitingNCT07266467Phase 4
- Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R RecipientsRecruitingNCT06798909Phase 3
- A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With GlioblastomaRecruitingNCT06102525Phase 1/2
- CMV Immunity Monitoring in Lung Transplant RecipientsRecruitingNCT05708755Phase 2
- Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment OutcomesTerminatedNCT03586284Phase 2/3Results posted
- Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesCompletedNCT03397706Phase 1/2Results posted
- Asymptomatic Congenital CMV TreatmentTerminatedNCT03301415Phase 2Results posted
- Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.CompletedNCT03296553Phase 2Results posted
- Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired InfantsTerminatedNCT03107871Phase 2Results posted
- A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT02871401Phase 1Results posted
- Valganciclovir Dosing in Pediatric Solid Organ Transplant RecipientsCompletedNCT02503982Phase 4Results posted
- A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus DiseaseTerminatedNCT02439970Phase 3Results posted
- A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of CytomegalovirusTerminatedNCT02439957Phase 3Results posted
- A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched ControlsCompletedNCT01663740Phase 4Results posted
- Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing LossCompletedNCT01649869Phase 2Results posted
- CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")CompletedNCT01552369Phase 4Results posted
- A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant RecipientsCompletedNCT01376804Phase 4Results posted
- Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to RecipientsCompletedNCT01329185Phase 2Results posted
- Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV InfectionsCompletedNCT00466817Phase 3Results posted
- A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.CompletedNCT00377741Phase 1Results posted
- A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal TransplantationCompletedNCT00372229Phase 3Results posted
- IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft RecipientsCompletedNCT00294515Phase 3Results posted
- Valganciclovir to Reduce T Cell Activation in HIV InfectionCompletedNCT00264290Phase 4Results posted
- Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung TransplantationCompletedNCT00227370Phase 3Results posted
- Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's SarcomaCompletedNCT00096538Not applicableResults posted
- A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant RecipientsCompletedNCT00090766Phase 2/3Results posted
- Phase 1 Study of GEN2 in Patients With Advanced Solid TumorsTerminatedNCT06391918Phase 1
- ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSIONCompletedNCT04724447Phase 1/2
- A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma PatientsActive, not recruitingNCT04116411Phase 2
- Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab TherapyTerminatedNCT04064697Phase 3
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaCompletedNCT03915366Phase 2/3
- Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.CompletedNCT03699254Phase 3
- Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic ValganciclovirCompletedNCT03631316Not applicable
- Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02761291Phase 1
- Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and BalanceTerminatedNCT02606266Phase 2/3
- Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting ConditionCompletedNCT02297854Phase 1
- Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed ConditionCompletedNCT02296723Phase 1
- Congenital Cytomegalovirus: Efficacy of Antiviral TreatmentCompletedNCT02005822Phase 3
- Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled TrialTerminatedNCT01655212Phase 3
- Cytomegalovirus Control in Critical CareCompletedNCT01503918Phase 2
- Antiviral Treatment of Chronic Lymphocytic LeukemiaCompletedNCT01255644Phase 4
- Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell TransplantationTerminatedNCT01185223Phase 3
- A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of AgeCompletedNCT01165580Phase 1
- Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative DisordersTerminatedNCT00992732Phase 2
- Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus TherapyStatus unknownNCT00966836Phase 3
- Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)CompletedNCT00947141Phase 4
- Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid MalignanciesTerminatedNCT00917826Phase 2
- Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant PatientsStatus unknownNCT00828503Phase 2
- Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant PatientsCompletedNCT00730769Phase 4
- Oral Valganciclovir Versus ValacyclovirCompletedNCT00562770Phase 2
- Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)CompletedNCT00478465Phase 1/2
- VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant RecipientsCompletedNCT00431353Phase 4
- Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) InfectionCompletedNCT00400322Not applicable
- Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive CancerWithdrawnNCT00387530Phase 2
- TAMOVALCIR in Allogenic Hematopoietic Progenitors TransplantCompletedNCT00386412Phase 2
- Study of Prophylactic Vs Preemptive ValganciclovirCompletedNCT00374686Not applicable
- Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's DiseaseWithdrawnNCT00361933Phase 4
- Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)CompletedNCT00330018Phase 3
- The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.CompletedNCT00275665Phase 3
- WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant RecipientsTerminatedNCT00275314Phase 3
- Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell TransplantTerminatedNCT00241345Phase 3
- MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by CytomegalovirusTerminatedNCT00237653Phase 3
- Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion LymphomaCompletedNCT00217503Phase 2
- Suppression of Oral HHV8 Shedding With ValganciclovirCompletedNCT00194467Phase 2
- Pharmacokinetics of Mmf and ValganciclovirCompletedNCT00189150Phase 4
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 2
- Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant RecipientsCompletedNCT00034385Phase 4
- Valganciclovir in Congenital CMV InfantsCompletedNCT00031434Phase 1/2
- Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by InjectionStatus unknownNCT00017784Phase 3
- Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell TransplantationCompletedNCT00016068Phase 3
- Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIVCompletedNCT00006145Phase 3
- A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the EyesCompletedNCT00002377Phase 3
- A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDSCompletedNCT00002222Not applicable